AbbVie Inc.
—- Market cap
- —
- Debt
- +$65.00B
- Cash
- −$5.23B
Complete market value, debt and cash evidence is required for enterprise value.
Quick read
Fair value engine
Each company valued on the other's multiple, then compared with the market price.
ABBV · price snapshot
—Price unavailable
Implied fair value · at AMGN's multiple
—
Needs AMGN P/E.
AMGN · price snapshot
—Price unavailable
Implied fair value · at ABBV's multiple
—
Needs ABBV P/E.
Metric by metric
Smart diff
Where each company leads, and how wide the gap is.
6 metrics shown
MetricABBVAMGNDifference (ABBV − AMGN)
Revenue growth (YoY)
Growth lag
8.6%
10.0%
AMGN: higher Revenue growth (YoY) by 1.4 percentage points
Gross margin
Reported gross margin
70.2%
67.2%
ABBV: higher Gross margin by 3.0 percentage points
EBITDA proxy margin
Operating income + D&A
38.0%
38.8%
AMGN: higher EBITDA proxy margin by 0.8 percentage points
EV/Revenue
Lower is better
N/M
N/M
Insufficient data
P/E
Not comparable
N/M
N/M
Not comparable
Net debt / EBITDA proxy
Lower leverage
2.6
3.2
ABBV: lower Net debt / EBITDA proxy by 0.6
Statements
Side-by-side financials
Annual statements in reported currencies, with calculations and source evidence.
Income statement · reported unitsABBVAMGNDelta
RevenueEnded 2025-12-31Ended 2025-12-31+USD 24.41B
Gross profitEnded 2025-12-31Ended 2025-12-31+USD 18.24B
Operating incomeEnded 2025-12-31Ended 2025-12-31+USD 6B
EBITDA proxyEnded 2025-12-31Ended 2025-12-31+USD 8.97B
Net incomeEnded 2025-12-31Ended 2025-12-31−USD 3.49B
Diluted / combined EPS (reported share)Ended 2025-12-31Ended 2025-12-31Different share bases
Revenue growthEnded 2025-12-31Ended 2025-12-31−1.4 pp
Gross marginEnded 2025-12-31Ended 2025-12-31+3.0 pp
Operating marginEnded 2025-12-31Ended 2025-12-31−0.1 pp
EBITDA proxy marginEnded 2025-12-31Ended 2025-12-31−0.8 pp
Net marginEnded 2025-12-31Ended 2025-12-31−14.1 pp
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Historical trends
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
ABBVAMGN
Price framework
Enterprise value
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Amgen Inc.
—Price framework
Intrinsic value (DCF)
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
AbbVie Inc. · implied price per share
$92.88
$164.68B equity value÷1.77B shares=$92.88
Bear
$74.44
Base
$92.88
Bull
$117.70
Cash-flow base$18B
Growth1.8%
Discount rate10.5%
Balance sheet health
Solvency
Inspect reported liquidity and leverage alongside historical financial-health checks.
Piotroski F-Score
Financial strength on a 0–9 scale.
6/ 9 · ABBVModerate
6/ 9 · AMGNModerate
Altman Z-Score
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Relative positioning
Where the pair sits against the wider comparable set.
Keep comparing
More comparisons
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.